Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.6 Billion
- Q3 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 817,600 shares of SNDX stock, worth $13 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
817,600
Previous 860,000
4.93%
Holding current value
$13 Million
Previous $17.7 Million
10.86%
% of portfolio
0.03%
Previous 0.03%
Shares
21 transactions
Others Institutions Holding SNDX
# of Institutions
227Shares Held
88.3MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$126 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$93.2 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$79.5 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$77.9 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$65.5 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $902M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...